EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS
Abstract
Key words: children, juvenile rheumatoid arthritis, rituximab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(3):132-138)
About the Authors
K.B. IsaevaRussian Federation
E.I. Alexeeva
Russian Federation
R.V. Denisova
Russian Federation
T.M. Bzarova
Russian Federation
S.I. Valieva
Russian Federation
A.O. Lisitsin
Russian Federation
E.Yu. Gudkova
Russian Federation
E.L. Semikina
Russian Federation
E.A. Kopyl'tsova
Russian Federation
References
1. Бзарова Т.М, Алексеева Е.И., Петеркова В.А. Роль факторов болезни и факторов противоревматической терапии в развитии низкорослости у детей, страдающих ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (5): 13–18.
2. Smolen J.S., Redlich K., Zwerina J. et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin. Rev. Allergy. Immunol. 2005; 28 (3): 239–248.
3. Goldblatt F., Isenberg D.A. New therapies for rheumatoid arthritis. Clin. Exp. Vienna Immunol. 2005; 140 (2): 195–204.
4. Keystone E. B cell targeted therapies. Arthritis Res. Ther. 2005; 7 (Suppl. 3): 13–18.
5. Shaw T., Quan J., Totoritis M.C. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann. Rheum. Dis. 2003; 62 (Suppl. 2): 55–60.
6. Kotzin B.L. The role of B cells in the pathogenesis of rheumatoid arthritis. J. Rheumatol. Suppl. 2005; 73 (1): 14–18.
7. Looney R.J. B cell targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs. 2006; 66 (5): 625–639.
8. Lee S.J., Yedla P., Kavanaugh A. Secondary immune deficiencies associated with biological therapeutics. Curr. Allergy Asthma Rep. 2003; 3 (5): 389–395.
9. Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J. Rheumatol. 2008; 35 (7): 1245–1255.
10. Cohen S.B. B-cell depletion for rheumatic diseases: where are we? Med. Gen. Med. 2005; 7: 72.
11. Youinou P., Jamin C., Saraux A. B–cell: a logical target for treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 2007; 25 (2): 318–328.
12. Zhang Z., Bridges S.L. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum. Dis. Clin. North Am. 2001; 27: 335–353.
13. Cragg M.S., Walshe C.A., Ivanov A.O. et al. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 2005; 8: 140–174.
14. Atzeni F., Doria A., Maurizio T., Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 2007; 6 (8): 553–558.
15. Friedberg J.W. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am. Soc. Hematol. Educ. Program. 2005: 329–334.
16. Johnson P., Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin. Oncol. 2003; 30 (Supp. 2): 3–8.
17. Edwards J.C., Szczepanski L., Szechinski J. et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350 (25): 2572–2581.
18. Keystone E, Fleischmann R., Emery P., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007; 56 (12): 3896–3908.
19. Emery P., Fleischmann R., Filipowicz–Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double blind, placebo controlled, dose ranging trial. Arthritis Rheum. 2006; 54 (5): 1390–1400.
20. Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54 (9): 2793–2806.
21. Caporali R., Caprioli M., Bobbio-Pallavicini F. et al. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev. 2009; 8 (7): 591–594.
22. Насонов Е.Л., Лукина Г.В., Сигидин Я.А. и др. Применение моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите в России (предварительные результаты Российского регистра). Терапевтический архив. 2008; 80 (8): 57–62.
23. Алексеева Е.И., Бзарова Т.М., Валиева С.И. и др. Ритуксимаб: новые возможности лечения тяжелого рефрактерного ювенильного артрита. Вопросы современной педиатрии. 2008; 7 (2): 22–30.
24. Алексеева Е.И., Семикина Е.Л., Бзарова Т.М. и др. Опыт применения ритуксимаба у больной с системным вариантом юношеского артрита. Вопросы современной педиатрии. 2008; 7 (3): 79–85.
25. Алексеева Е.И., Семикина Е.Л., Бзарова Т.М. и др. Опыт применения ритуксимаба у больной системным ювенильным ревматоидным артритом. Вопросы современной педиатрии. 2006; 5 (6): 96–100.
26. Алексеева Е.И., Акулова С.С., Семикина Е.Л. и др. Эффективность ритуксимаба у больной системным вариантом юношеского артрита, рефрактерного к терапии традиционными иммунодепрессантами и блокаторами ФНО–α. Вопросы современной педиатрии. 2007; 6 (3): 94–100.
Review
For citations:
Isaeva K., Alexeeva E., Denisova R., Bzarova T., Valieva S., Lisitsin A., Gudkova E., Semikina E., Kopyl'tsova E. EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2009;8(3):132-138.
Email this article 
